Skip to main content

Advertisement

Fig. 5 | Virology Journal

Fig. 5

From: Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines

Fig. 5

Indirect anti-tumor effect of intratumoral CV-B3/2035A administration on untreated contralateral EC xenografts in vivo. a Five consecutive doses of CV-B3/2035A (5 × 106 TCID50 per dose) or PBS (Mock) were administered intratumorally (i.t.) into the right flank tumors in nude mice bearing bilateral HEC-1-B xenografts (n = 5 per group). Tumor growth (solid symbols) and body weight (open symbols) of the treated nude mice were monitored over a 20-day period. Statistical analysis was performed by two-way ANOVA. Data are shown in means ± SD. Each symbol represents the statistical significance of right (†) and left (#) lateral tumors between untreated and CV-B3/2035A-treated groups. Black arrows indicate treatments; ns, not significant. b Nude mice (n = 5 per group) were bled via the saphenous vein 1 h, 2 and 6 days post-treatment. Infectious CV-B3/2035A in the serum was determined by TCID50 assay on RD cells. The viremia levels (TCID50/ml) are shown in means ± SD. c Untreated contralateral HEC-1-B xenografts (n = 3) were collected from nude mice 1 h, 2 and 6 days post-treatment. Tumor samples were cut into pieces and homogenized with a Dounce tissue grinder (Sigma-Aldrich, USA) in ice-cold MEM, followed by a freeze-thaw protocol to release virus from cells. Clarified (centrifugation) supernatants were used to perform TCID50 assay on RD cells. Virus titers (TCID50/g tissue) are shown in means ± SD. *p < 0.05. d Tissue sections of untreated contralateral HEC-1-B xenografts from nude mice 20 days post-treatment were immunostained using antibodies specific for CV-B3 or murine IgG control. The inset boxes represent higher magnification images of the areas outlined by the dotted lines in the two panels

Back to article page